Clearview Simplify D-dimer is a rapid two-step test for the
detection of D-dimer.
Clearly different
Clearview's patented innovative technology provides highly
sensitive and specific tests for D-dimer.
- Fast: two easy steps with results in
10 minutes
- Easy: simple test requires no
expensive instrumentation or specialized training
- Reliable: built-in control ensures
accuracy
- Flexible: faster results while the
patient waits
Clearly
better
Clearview Simplify D-dimer offers important benefits for you and
your patients.
- Aids in the diagnosis of deep vein thrombosis (DVT), pulmonary
embolism (PE), and disseminated intravascular coagulation
(DIC)
- Utilizes the patented 3B6/22 Monoclonal Antibody, specific only
for D-dimer, which minimizes the false positives that can be seen
with competitive tests
- Reduces the wait for test results
- Can be performed by any staff member, eliminating the need for
instrumentation and specialized training
Clearview®
SIMPLIFY® D-dimer Test Procedure
- Whole blood: Use disposable pipette to
transfer 1 drop of whole blood (35 µL) to the sample well.
- Plasma: Use a laboratory pipette (not
provided) to dispense 20 µL of plasma to the sample well. DO NOT
use the disposable pipette.
Apply 2 drops of Clearview Simplify Buffer to
the sample well.
Read result in 10 minutes. For full
instructions for use, see package insert.
About Thrombosis
A deep vein thrombosis (DVT) is a blood clot that forms in the
body's deep veins, usually in the leg or hip veins. In some cases,
the clot breaks off, travels through the bloodstream, and obstructs
a vessel in the lungs, restricting blood flow. This condition,
called pulmonary embolism (PE), can be life-threatening. Venous
thromboembolism (VTE; refers to DVT, PE, or a combination of both)
affects as many as 2 million people every year in the
U.S.1
During blood coagulation, fibrinogen is converted to fibrin by
the activation of thrombin. The resulting fibrin monomers
polymerize to form a soluble gel of non-cross-linked fibrin. This
fibrin gel is then converted to cross-linked fibrin by thrombin
activated Factor XIII to form an insoluble fibrin clot. Production
of plasmin, the major clot lysing enzyme, is triggered when a
fibrin clot is formed. Although fibrinogen and fibrin are both
cleaved by the fibrinolytic enzyme plasmin to yield degradation
products, only degradation products from cross-linked fibrin
contain D-dimer and are called cross-linked fibrin degradation
products.2-4 Therefore, fibrin derivatives in human
blood or plasma containing D-dimer are a specific marker of
fibrinolysis.
References
- Goldhaber SZ, Morrison RB. Cardiology Patient Page: Pulmonary
embolism and deep vein thrombosis. Circulation.
2002;106:1436-1438.
- Gaffney PJ. Distinction between fibrinogen and fibrin
degradation products in plasma. Clin Chim Acta.
1978;65(1):109-115.
- Lane DA, et al. Characterization of serum fibrinogen and fibrin
fragments produced during disseminated intravascular coagulation.
Br J Haematol. 1978;40(4):609-615.
- Rylatt DB, et al. An immunoassay for human D-dimer using
monoclonal antibodies. Thromb Res. 1980;18(3-4):453-459.